Molecular Imaging of Infections: Advancing the Search for the Hidden Enemy.

Autor:	Hammoud DA; Center for Infectious Disease Imaging, Radiology and Imaging Sciences, NIH Clinical Center, Bethesda, Maryland, USA., Clifford Lane H; National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA., Jain SK; Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Jazyk:	angličtina
Zdroj:	The Journal of infectious diseases [J Infect Dis] 2023 Oct 03; Vol. 228 (Suppl 4), pp. S233-S236.
DOI:	10.1093/infdis/jiad079
Abstrakt:	Even before the coronavirus disease 2019 pandemic, infections were a major threat to human health, as the third leading cause of death and the leading cause of morbidity among all human diseases. Although conventional imaging studies are routinely used for patients with infections, they provide structural or anatomic information only. Molecular imaging technologies enable noninvasive visualization of molecular processes at the cellular level within intact living subjects, including patients, and hold great potential for infections. We hope that this supplement will spur interest in the field and establish new collaborations to develop and translate novel molecular imaging approaches to the clinic. Competing Interests: Potential conflicts of interest. DAH is first named inventor for pending patent application US2020/044446 on radiolabeled sugars for imaging of fungal infections, filed by the NIH. SKJ is an inventor for patent US20150250906A1 on bacteria-specific labeled substrates as imaging biomarkers, filed by Johns Hopkins University; SKJ is an inventor for pending patent USPA #63/071,755 on the solid-phase cartridge to formulate ready-to-use 18F-FDS, filed by Johns Hopkins University. SKJ has research grants from Novobiotic LLC, USA, T3 Pharma, Switzerland, and Fujirebio Diagnostics, Inc., USA and is a scientific consultant for Novobiotic LLC, USA. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu